## Summary of evidence and Expert Committee recommendations

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for tamoxifen on the complementary list of the EML for use in treatment protocols for hormone-receptor positive early stage breast cancer was specifically endorsed. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for early stage breast cancer is attached.